Dive Brief:
- PA-based Zynerba plans to move into clinical trials with cannibinoid-laced transdermal patches (ZYN001 and ZYN002) for treatment of various central nervous system (CNS) diseases. The company has raised $42 million in an IPO to help fund its ambitions.
- Zynerba's transdermal patches have shown promise in refractory epilepsy, Fragile X syndrome, and osteoparthritis, as well as fibromyalgia and peripheral neuropathic pain.
- One of the major advantages associated with Zynerba's patches is that they use synthetically manufactured cannabinoids and therefore are not dependent on growing cannabis plants.
Dive Insight:
Zynerba has the distinct advantage of a product that is synthetically manufactured and also has direct-to-CNS delivery. In addition, its headed up by Armando Anido, who comes with strong industry experience, including heading up Auxilium Pharmaceuticals (acquired by Endo last year for $2.6 billion) and NuPathe (acquired by Teva for $144 million)
It seems that the company's high hopes are well grounded, with all signs pointing to a promising IPO.